Real-World Effectiveness and Safety of Glofitamab in Primary Refractory and Early Relapsed Diffuse Large B-Cell Lymphoma
Henan Cancer Hospital
Henan Cancer Hospital
ModeX Therapeutics, An OPKO Health Company
Stanford University
Poseida Therapeutics, Inc.
Dana-Farber Cancer Institute
LTZ Therapeutics, Inc.
The First Affiliated Hospital with Nanjing Medical University
Chengdu Zenitar Biomedical Technology Co., Ltd
Eli Lilly and Company
Virginia Commonwealth University
Miltenyi Biomedicine GmbH
Masonic Cancer Center, University of Minnesota
Stichting Hemato-Oncologie voor Volwassenen Nederland
Verismo Therapeutics
Memorial Sloan Kettering Cancer Center
GenomeFrontier Therapeutics TW Co., Ltd.
H. Lee Moffitt Cancer Center and Research Institute
University Health Network, Toronto
The First Affiliated Hospital of Soochow University
Sun Yat-sen University
University of Arizona
Mayo Clinic
Memorial Sloan Kettering Cancer Center
Chengdu Zenitar Biomedical Technology Co., Ltd
University of Nebraska
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Insel Gruppe AG, University Hospital Bern
The Lymphoma Academic Research Organisation
Medical University of Vienna
Florida International University
Ain Shams University
Masonic Cancer Center, University of Minnesota
Institute of Hematology & Blood Diseases Hospital, China
City of Hope Medical Center
Masonic Cancer Center, University of Minnesota
Pell Bio-Med Technology Co., Ltd.
ImmunityBio, Inc.
The First Affiliated Hospital of Xiamen University
The First Affiliated Hospital of Xiamen University
Durham VA Medical Center
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Nkarta, Inc.
Ruijin Hospital
Université de Sherbrooke
University Medical Center Groningen
Zhejiang Provincial People's Hospital
University Medical Center Goettingen
Gruppo Italiano Malattie EMatologiche dell'Adulto
Australasian Leukaemia and Lymphoma Group